Detalhe da pesquisa
1.
Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Blood
; 137(4): 513-523, 2021 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507295
2.
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?
Gynecol Oncol
; 176: 36-42, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37442024
3.
Not all stage I and II endometrial cancers are created equal: Recurrence-free survival and cause-specific survival after observation or vaginal brachytherapy alone in all subgroups of early-stage high-intermediate and high-risk endometrial cancer.
Gynecol Oncol
; 167(3): 444-451, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36244826
4.
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Cancer
; 126(4): 894-907, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31714594
5.
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers.
Gynecol Oncol
; 146(1): 64-68, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28461031
6.
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
BMC Cancer
; 16(1): 814, 2016 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27765027
7.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Gynecol Oncol
; 143(2): 379-388, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27614696
8.
A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Clin Cancer Res
; 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38530846
9.
Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile.
Front Oncol
; 13: 1105504, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37287928
10.
Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling.
Genes (Basel)
; 14(6)2023 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37372428
11.
Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
Cancer Res
; 83(15): 2557-2571, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37253112
12.
High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.
Gynecol Oncol Rep
; 41: 100987, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35519002
13.
GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.
Cancer Res Commun
; 2(8): 784-794, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36082022
14.
Machine-learning aided in situ drug sensitivity screening predicts treatment outcomes in ovarian PDX tumors.
Transl Oncol
; 21: 101427, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35472731
15.
ECPPF (E2F1, CCNA2, POLE, PPP2R1A, FBXW7) stratification: Profiling high-risk subtypes of histomorphologically low-risk and treatment-insensitive endometrioid endometrial cancer.
PLoS One
; 17(12): e0278408, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36454788
16.
Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer.
Cancer Res
; 82(6): 1038-1054, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34654724
17.
Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.
Cancer Res
; 82(2): 307-319, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34810199
18.
DNA barcoded competitive clone-initiating cell analysis reveals novel features of metastatic growth in a cancer xenograft model.
NAR Cancer
; 4(3): zcac022, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35875052
19.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.
Cancer Res
; 82(23): 4457-4473, 2022 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36206301
20.
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Gynecol Oncol
; 122(1): 116-20, 2011 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-21514634